Report Overview

The Australian Sarcoglycanopathies Therapeutics Market size stood at around USD XX billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Limb-girdle muscular dystrophies (LGMD) are a group of rare progressive genetic disorders that are characterized by wasting (atrophy) and weakness of the voluntary muscles of the hip and shoulder areas (limb-girdle area). These forms of LGMD may range from a severe form often with childhood onset to a mild form often with adult onset. The severity varies greatly even among individuals of the same family. Early onset forms may cause progressive muscle weakness of the legs, hips, abdomen, and shoulder. The progression of muscle weakness of the Sarcoglycanopathies is often more rapid than with other forms of LGMD and affected individuals may need a wheelchair between 12-16 years of age. Individuals with later onset usually experience a slower progression and more mild symptoms. Such individuals usually retain the ability to walk independently late into adulthood. Additional symptoms are often associated with the Sarcoglycanopathies including overgrowth of the calf and tongue muscles, cardiomyopathy, respiratory abnormalities, contractures, and scoliosis.



Market Drivers

Increasing incidence of Sarcoglycanopathies Syndrome, rising health care industries, and increase in government investment to develop health care infrastructure also drive the market growth.

However, rising treatment costs and a lack of awareness among patients and physicians about Sarcoglycanopathies are among the major factors acting as restraints, and will continue to pose a challenge to the Sarcoglycanopathies Therapeutics market in the forecast period.